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1xclusive Antiplatelet Therapy for
ercutaneous Coronary Intervention
A journey of a thousand miles begins with a single step.
—Lao Tzu, ancient Chinese philosopher (1)
tabile et al. (2) indeed deserve congratulations for the clinical trial
hat they recently published in the Journal. It is the first step on a
ourney into exclusive dual antiplatelet therapy (aspirin and clopi-
ogrel) alone during percutaneous coronary intervention (PCI),
ithout scheduled antithrombin or glycoprotein inhibitor therapy.
owever, as pointed out in the accompanying editorial by Dauer-
an (3), there are several concerns with the trial. Specifically, the
pproach of dual antiplatelet therapy alone may lack an essential
safety net” that could be provided by antithrombin therapy or,
erhaps, glycoprotein inhibitor therapy.
Thrombosis during PCI and otherwise occurs through 2 inter-
elated mechanisms: first, the adhesion, activation, secretion, and
ggregation of platelets; and second, amplification of the coagulation
ascade, which requires an activated platelet surface for the develop-
ent of thrombin (4). In theory, if adequate antiplatelet therapy is
rovided, thrombosis will not occur, even in the absence of antithrom-
in therapy directed towards the coagulation cascade. This theory has
een supported by in vitro experiments dating back over 20 years (5).
Subsequent clinical research published 15 years ago involving a
ew class of drug, the glycoprotein IIb/IIIa inhibitors (e.g.,
bciximab), which block the final common pathway of platelet
ggregation, showed a significant decrease in ischemic complica-
ions during PCI at the expense of a significant increase in
leeding complications (6). These results created a dilemma for
hose interventional cardiologists (including myself) who already
ad a relatively high bleeding complication rate (7). Therefore, 12
ears ago, in an effort to optimize patient care, I changed from the
hen contemporary combination of dual antiplatelet therapy (as-
irin and ticlopidine) and a conventional dose of unfractionated
eparin to triple antiplatelet therapy (adding abciximab) and only
minimal dose of unfractionated heparin. The success of this
pproach (8) led me to take one step further 9 years ago to exclude
cheduled antithrombin therapy altogether for both elective, low
isk and urgent, higher risk PCI, while relying on triple antiplatelet
herapy (aspirin, clopidogrel, and eptifibatide) alone (9,10). De-
pite the success of this strategy in limiting both ischemic and
leeding complications, and despite subsequent support provided
y REMOVE (Reduction in Major and Minor Adverse Events
ith Eptifibatide-based Pharmacotherapy in Percutaneous Cor-
nary Intervention) (11), exclusive antiplatelet therapy drew skep-
icism and criticism from many of our cardiovascular colleagues.
he trial published by Stabile et al. (2) therefore provided timely
nd much needed support for the “exclusive antiplatelet therapy”
roponents.
Stabile et al. (2), however, was confined to very low-risk PCI,
nd the safety net concern expressed by Dauerman (3) poses a valid
1uestion. On the basis of theory, in vitro experiments and my own
xperiences, I believe that the safety net can be provided by
lycoprotein IIb/IIIa receptor inhibition, using abciximab, eptifi-
atide, or, perhaps, tirofiban. This approach of triple antiplatelet
herapy with minimal or no specific antithrombin therapy directed
owards the coagulation cascade during PCI will, in my opinion,
rove to be safe and efficacious for both elective, low-risk and
rgent, higher-risk PCI. Hopefully, this approach will be proved
y unbiased, well-designed randomized clinical trials that con-
inue the journeys initiated by the proponents of “exclusive
ntiplatelet therapy” during PCI, including Stabile et al. (2)
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e would like to thank Dr. Denardo for his interest in our work
1), and we appreciate his quoting a proverb that well depicts our
aper’s take-home message. The CIAO (Coronary Interventions
ntiplatelet-based Only) trial is a first step on a journey into
xclusive dual antiplatelet therapy (aspirin and thienopyridine)
lone during percutaneous coronary intervention (PCI), without
cheduled antithrombin or glycoprotein inhibitor therapy.
We disagree with the accompanying editorial (2), which states
hat dual antiplatelet therapy alone may lack an essential “safety
et” that could be provided by antithrombin therapy or, perhaps,
lycoprotein inhibitor therapy. As pointed out by Dr. Denardo,
he use of aspirin, combined with adequate patient pretreatment
ith a thienopyridine, will guarantee an adequate inhibition of
latelet activity and lack of triggering for the coagulation cascade
uring a planned PCI (3,4).
Moreover, the use of the glycoprotein IIb/IIIa inhibitors (e.g.,
bciximab) will not add a further inhibition of the the final
ommon pathway of platelet aggregation in stable patients in
hronic treatment with thienopiridine. Solid clinical data proving
he opposite are still lacking.
So far, the the only proof of this theory is the absence of
hrombotic occlusions and the lower ischemic complications dur-
ng PCI (i.e., periprocedural myocardial damage) in the placebo
roup of the CIAO trial (1).
An additional point is related to procedural costs. Our approach
s aimed at a safe and efficient removal of expensive, unnecessary
rugs from elective procedures. This is valid, both for inhibitors of
he anticoagulation cascade, and for glycoprotein IIb/IIIa receptor
nhibitors. We truly believe that these drugs, in this clinical setting,
an only increase the incidence of bleeding and raise the costs
ithout improving the patient’s outcome.
However, as pointed out by Dr. Denardo, further trials are
eeded to make a second step along this path. Testing our
ypothesis for the treatment of more complicated lesions is crucial
o prove the clinical value of CIAO findings.
Finally, we want to thank Dr. Denardo, who has inspired our
ork. Thanks to his pioneering experience, together with the
esults of the REMOVE (Reduction in Major and Minor Adverse
vents With Eptifibatide-based Pharmacotherapy in Percutaneous
oronary Intervention) (5) and CIAO (1) trials, exclusive anti-
latelet therapy is not considered heretical any more.
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Well some things you can explain away,
but the heartache’s in me till this day.
—The Clash, 1979 (1)
read with interest Dr. Denardo’s letter concerning the CIAO
Coronary Interventions Antiplatelet-based Only) trial (2) and the
ccompanying editorial (3). My congratulations are extended to
r. Denardo and other investigators who have found novel
pproaches to reducing bleeding complications associated with
ercutaneous coronary intervention (PCI), including the CIAO
pproach, fondaparinux, bivalirudin, reduced doses of unfraction-
ted heparin, improved femoral access technique, or radial artery
pproaches. As discussed in the editorial (3), caution is warranted
hen data are limited to selected lower-risk patient subsets.
Dr. Denardo’s letter, though, focuses congratulations on the
IAO trial as a “first step on a journey into exclusive dual antiplatelet
herapy.” As expressed in the editorial, there are pathophysiologic
oncerns about embarking on this journey in higher-risk subgroups of
atients. Specifically, concern arises with the statement: “if adequate
ntiplatelet therapy is provided, thrombosis will not occur, even in
he absence of antithrombin therapy. . . .” Arguments against
his hypothesis are the following:
During the REMOVE (Reduction in Major and Minor Ad-
verse Events With Eptifibatide-based Pharmacotherapy in Per-
cutaneous Coronary Intervention) trial, thrombus did form
during bifurcation PCI despite aspirin, clopidogrel, and glyco-
protein inhibition (GPI). Thus, the protocol was amended to
exclude these higher-risk lesions from a no-antithrombin ap-
proach (4).
Platelet activation is induced by vessel injury, exposure to
collagen, and a myriad of other agents. No antiplatelet agent
that is clinically available can inhibit all pathways of platelet
activation (5). Further, although GPI decreases platelet aggre-
gation and the quantity of platelets in a growing thrombus, it
may not prevent platelet adherence or platelet–leukocyte aggre-
gation that can contribute to thrombin formation (6).
Nonplatelet blood elements, particularly monocytes, support
thrombin generation (7). The exclusive antiplatelet therapy
approach would not necessarily prevent nonplatelet-mediated
generation of thrombin.
